BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 10,000 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 10,000 shares of BioLife Solutions stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $23.28, for a total value of $232,800.00. Following the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at $7,396,428.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

BioLife Solutions Stock Up 0.8 %

BLFS stock opened at $23.14 on Friday. The firm has a market cap of $1.07 billion, a PE ratio of -16.30 and a beta of 1.88. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.81 and a current ratio of 2.86. BioLife Solutions, Inc. has a one year low of $8.92 and a one year high of $26.73. The firm’s 50 day moving average price is $24.64 and its 200-day moving average price is $21.72.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. The company had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. On average, equities research analysts anticipate that BioLife Solutions, Inc. will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BLFS. Northland Securities raised their target price on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. TD Cowen lifted their price objective on BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, July 17th. Craig Hallum boosted their target price on BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, HC Wainwright began coverage on BioLife Solutions in a report on Monday, September 30th. They set a “buy” rating and a $29.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and a consensus price target of $26.67.

Hedge Funds Weigh In On BioLife Solutions

Several institutional investors have recently modified their holdings of BLFS. 1620 Investment Advisors Inc. acquired a new position in shares of BioLife Solutions in the second quarter worth $35,000. Isthmus Partners LLC grew its stake in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 42,265 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares in the last quarter. Register Financial Advisors LLC acquired a new position in shares of BioLife Solutions in the first quarter worth $96,000. Finally, Canada Pension Plan Investment Board acquired a new position in shares of BioLife Solutions in the second quarter worth $122,000. Institutional investors and hedge funds own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.